AnGes, Inc. (TYO:4563)
Japan · Delayed Price · Currency is JPY 36.00
0.00 (0.00%)
Sep 16, 2026, 3:06 PM JST
AnGes Revenue
AnGes had revenue of 299.00M JPY in the quarter ending June 30, 2026, with 22.04% growth. This brings the company's revenue in the last twelve months to 962.00M, up 35.49% year-over-year. In the year 2025, AnGes had annual revenue of 874.00M with 35.93% growth.
Revenue (ttm)
962.00M
Revenue Growth
+35.49%
P/S Ratio
14.93
Revenue / Employee
17.18M
Employees
56
Market Cap
14.36B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 874.00M | 231.00M | 35.93% |
| Dec 31, 2024 | 643.00M | 491.00M | 323.03% |
| Dec 31, 2023 | 152.00M | 85.00M | 126.87% |
| Dec 31, 2022 | 67.00M | 3.00M | 4.69% |
| Dec 31, 2021 | 64.00M | 25.00M | 64.10% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| RaQualia Pharma | 3.90B |
| ReproCELL | 2.30B |
| Immuno-Biological Laboratories | 1.08B |
| OncoTherapy Science | 777.00M |
| Carna Biosciences | 729.00M |
| Stella Pharma | 323.00M |
| Nano Holdings | 202.00M |
| Kubota Pharmaceutical Holdings | 16.00M |